Experimental cancer drug trial halted early – what happened?

NCT ID NCT06563804

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times

Summary

This study tested a new drug called S227928, alone or with another drug (venetoclax), in 13 people with blood cancers that had come back or stopped responding to treatment. The goal was to find a safe dose and see if it could shrink the cancer. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU de Bordeaux - Hopital du Haut Levêque

    Pessac, 33604, France

  • Chu de Nice - Hôpital L'archet 1

    Nice, 062000, France

  • City of Hope

    Duarte, California, 91010, United States

  • Fred Hutch Cancer Center

    Seattle, Washington, 98109, United States

  • Helsinki University Hospital - Comprehensive Cancer Center

    Helsinki, 00029, Finland

  • Institut Gustave Roussy

    Villejuif, 94800, France

  • Institut Paoli Calmette

    Marseille, 13009, France

  • Klinikum rechts der Isar der TU München

    München, 81675, Germany

  • Memorial Sloan Kettering

    New York, New York, 10065, United States

  • Peter MacCallum Cancer Centre

    Melbourne, 3000, Australia

  • Prince of Wales Hospital

    Randwick, 2031, Australia

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • Sapporo Hokuyu Hospital

    Hokkaido, 003-0006, Japan

  • The University of Kansas

    Fairway, Kansas, 66205, United States

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    Tokyo, 113-8677, Japan

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.